Background: The long-term stability of the breast shape, once it is achieved, should be included among the principal concerns of aesthetic mammaplasty. This goal presents a particular challenge to the surgeon treating a patient who is concerned with breast lift but also wants to preserve or even increase cup size.

Objective: This report details the use of a lower myofascial supportive flap (MFF) to prevent secondary breast ptosis in various clinical situations.

Methods: The conceptual approach was to use the MFF to reconstruct or make up for deficiencies of the superficial fascial system collagen network, which in this surgeon's view plays a key role in determining breast position and shape. The MFF flap was raised in the region of the pectoralis major and adjacent muscles based at the inframammary fold (IMF) level and sutured near the lower areola border, with the goal of recreating the IMF, stabilizing the nipple-fold distance, and providing long-term support to counteract the effects of gravity through the creation of a "balcony" flap within which the lower breast pole rests. The procedure was performed in various clinical situations, including primary mastopexy, secondary mastopexy to correct for "bottoming out" after previous surgery, mastopexy with augmentation, implant exchange plus mastopexy, and simple primary augmentation.

Results: The use of the MFF provided an aesthetic breast shape while maintaining upper-pole fullness. Morbidity was highest among patients who underwent primary or secondary mastopexy and lowest among those who underwent simple primary augmentation. However, in the latter group, morbidity was notably higher than in patients who underwent simple primary augmentation without the use of the MFF.

Conclusions: The MFF technique can provide better long-standing breast support than other procedures aimed at preventing or minimizing secondary breast ptosis. It is indicated most clearly for patients who are unwilling to give up breast volume for improved breast shape and who are unhappy with the results of previous standard mastopexy or augmentation. It is less useful in patients undergoing primary breast lift. Limitations include increased duration of surgery and increased trauma.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.asj.2004.04.002DOI Listing

Publication Analysis

Top Keywords

breast
12
breast shape
12
simple primary
12
aesthetic breast
8
breast lift
8
secondary breast
8
breast ptosis
8
secondary mastopexy
8
mastopexy augmentation
8
patients underwent
8

Similar Publications

Breast cancer remains the leading cause of mortality among women with cancer. This article delves into the intricate relationship between breast cancer and cancer stem cells (CSCs), emphasizing advanced methods for their identification and isolation. The key isolation techniques, such as the mammosphere formation assay, surface marker identification, Side Population assay, and Aldehyde Dehydrogenase assay, are critically examined.

View Article and Find Full Text PDF

Epidermal growth factor receptor (EGFR) plays an important role in the regulation of cell proliferation and migration [1]. It forms a homodimer or heterodimer with other ErbB receptor family members to activate downstream signaling. Emerging evidence indicates that the EGFR activity and downstream signaling are regulated by other proteins except its family members during tumorigenesis.

View Article and Find Full Text PDF

Purpose: Perfusion modeling presents significant opportunities for imaging biomarker development in breast cancer but has historically been held back by the need for data beyond the clinical standard of care (SoC) and uncertainty in the interpretability of results. We aimed to design a perfusion model applicable to breast cancer SoC dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) series with results stable to low temporal resolution imaging, comparable with published results using full-resolution DCE-MRI, and correlative with orthogonal imaging modalities indicative of biophysical markers.

Methods: Subsampled high-temporal-resolution DCE-MRI series were run through our perfusion model and resulting fits were compared for consistency.

View Article and Find Full Text PDF

Background: We aimed to investigate the clinical and molecular characteristics of different degrees of human epidermal growth factor receptor 2 (HER2) protein expression in HER2-negative breast cancer and the related factors affecting the efficacy of neoadjuvant chemotherapy in HER2-low breast cancer patients.

Methods: The study endpoint was pathological complete remission (PCR). Blood specimens and fresh cancer tissue samples were collected before neoadjuvant chemotherapy for whole-exon sequencing (WES) and RNA sequencing (RNA-seq), and patients were divided into a human epidermal growth factor receptor 2 (HER2)-low group and a HER2-0 group according to their HER2 expression status via bioinformatics analysis.

View Article and Find Full Text PDF

This study aimed to evaluate the efficacy of pyrotinib, an orally administered small molecule tyrosine kinase inhibitor, combined with neoadjuvant chemotherapy in treating patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Pyrotinib works by inhibiting the HER2 signaling pathway, thereby preventing tumor cell growth. This single-arm clinical trial aimed to assess the total pathological complete response (tpCR; ypT0/is and ypN0) rate as the primary endpoint.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!